0,31 $
0,98 %
Nasdaq, Mo, 26.02.2024
ISIN
US42237K3005
Symbol
HTBX
Berichte
Sektor
Industrie

Heat Biologics, Inc. Aktie News

Neutral
GlobeNewsWire
fast 2 Jahre alt
500,000+ square foot facility  to support commercial-scale biomanufacturing
Neutral
GlobeNewsWire
fast 2 Jahre alt
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest ...
Neutral
GlobeNewsWire
fast 2 Jahre alt
Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats
Neutral
GlobeNewsWire
etwa 2 Jahre alt
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023
Neutral
GlobeNewsWire
etwa 2 Jahre alt
Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom
Neutral
GlobeNewsWire
etwa 2 Jahre alt
Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations
Neutral
GlobeNewsWire
mehr als 2 Jahre alt
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy.
Neutral
GlobeNewsWire
mehr als 2 Jahre alt
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen